Abstract B029: Differential safety profiles of PD-1 inhibitors: A comparative pharmacovigilance analysis of immune-related adverse events with pembrolizumab and nivolumab in FAERS (2015–2024)
Year: 2026
Type: conference-abstract
Source: Cancer Immunology Research
Authors: Zehra Rahman, Oday Elmanaseer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7130537947
Cites:
Cited by:
Related to: